John L. Silberstein

2.3k total citations · 1 hit paper
16 papers, 1.0k citations indexed

About

John L. Silberstein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, John L. Silberstein has authored 16 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in John L. Silberstein's work include Prostate Cancer Treatment and Research (11 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). John L. Silberstein is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). John L. Silberstein collaborates with scholars based in United States, France and Belgium. John L. Silberstein's co-authors include Emmanuel S. Antonarakis, Jun Luo, Changxue Lu, Hao Wang, Brandon Luber, Mario A. Eisenberger, Michael A. Carducci, Maritza N. Taylor, Channing J. Paller and Samuel R. Denmeade and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

John L. Silberstein

16 papers receiving 993 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

2017 340 citations Emmanuel S. Antonarakis, Changxue Lu et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John L. Silberstein United States	12	728	413	323	314	147	16	1.0k
Fabian Zohren United States	14	690 0.9×	288 0.7×	230 0.7×	331 1.1×	67 0.5×	44	1.1k
Michael Kolinsky Canada	13	572 0.8×	361 0.9×	197 0.6×	182 0.6×	62 0.4×	54	824
Penelope Flohr United Kingdom	10	771 1.1×	302 0.7×	555 1.7×	439 1.4×	49 0.3×	25	1.1k
Mateus Crespo United Kingdom	17	525 0.7×	421 1.0×	393 1.2×	399 1.3×	61 0.4×	44	1.0k
Jessica Louw United States	9	692 1.0×	479 1.2×	532 1.6×	249 0.8×	53 0.4×	30	988
Adam Jendrisak United States	10	679 0.9×	510 1.2×	518 1.6×	255 0.8×	65 0.4×	32	988
Μαρία Κάρλου Greece	13	477 0.7×	177 0.4×	211 0.7×	282 0.9×	29 0.2×	19	739
Sam Leung Canada	8	214 0.3×	238 0.6×	244 0.8×	332 1.1×	138 0.9×	13	808
Victor Reuter United States	13	694 1.0×	163 0.4×	309 1.0×	375 1.2×	38 0.3×	19	1.1k
Brian McConeghy Canada	11	624 0.9×	176 0.4×	498 1.5×	311 1.0×	21 0.1×	15	853

Countries citing papers authored by John L. Silberstein

Since Specialization

Citations

This map shows the geographic impact of John L. Silberstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Silberstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Silberstein more than expected).

Fields of papers citing papers by John L. Silberstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Silberstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Silberstein. The network helps show where John L. Silberstein may publish in the future.

Co-authorship network of co-authors of John L. Silberstein

This figure shows the co-authorship network connecting the top 25 collaborators of John L. Silberstein. A scholar is included among the top collaborators of John L. Silberstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Silberstein. John L. Silberstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Silberstein, John L., Jasper Du, Kun‐Wei Chan, et al.. (2024). Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function. Proceedings of the National Academy of Sciences. 121(12). e2310866121–e2310866121. 27 indexed citations

Silberstein, John L., et al.. (2022). Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. Journal for ImmunoTherapy of Cancer. 10(5). e004693–e004693. 47 indexed citations

Bhamidipati, Kartik, John L. Silberstein, Yashaar Chaichian, et al.. (2021). CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function. Frontiers in Immunology. 11. 626820–626820. 22 indexed citations

Kelly, Ryan L., Robert Lee, Sean A. Yamada‐Hunter, et al.. (2020). An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Scientific Reports. 10(1). 15171–15171. 49 indexed citations

Antonarakis, Emmanuel S., Changxue Lu, Brandon Luber, et al.. (2018). Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. European Urology. 74(2). 218–225. 132 indexed citations

Velho, Pedro Isaacsson, John L. Silberstein, Mark C. Markowski, et al.. (2018). Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer. The Prostate. 78(5). 401–407. 88 indexed citations

Armstrong, Andrew J., Susan Halabi, Jun Luo, et al.. (2018). The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).. Journal of Clinical Oncology. 36(15_suppl). 5004–5004. 10 indexed citations

Teply, Benjamin A., Hao Wang, Brandon Luber, et al.. (2017). Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. The Lancet Oncology. 19(1). 76–86. 137 indexed citations

Boudadi, Karim, Daniel L. Suzman, Brandon Luber, et al.. (2017). Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). 5035–5035. 24 indexed citations

10.

Markowski, Mark C., John L. Silberstein, James R. Eshleman, et al.. (2017). Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology. 2017(1). 1–9. 45 indexed citations

11.

Antonarakis, Emmanuel S., Changxue Lu, Brandon Luber, et al.. (2017). Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Journal of Clinical Oncology. 35(19). 2149–2156. 340 indexed citations breakdown →

12.

Silberstein, John L., Brandon Luber, Hao Wang, et al.. (2017). Clinical significance of AR mRNA quantification from circulating tumor cells (CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (Abi) or enzalutamide (Enza).. Journal of Clinical Oncology. 35(6_suppl). 132–132. 4 indexed citations

13.

Lokhandwala, Parvez M., Lisa Haley, Changxue Lu, et al.. (2016). Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics. 19(1). 115–125. 41 indexed citations

14.

Silberstein, John L., Maritza N. Taylor, & Emmanuel S. Antonarakis. (2016). Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer. Current Urology Reports. 17(4). 29–29. 23 indexed citations

15.

Boudadi, Karim, Daniel L. Suzman, Brandon Luber, et al.. (2016). STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). TPS5089–TPS5089. 1 indexed citations

16.

Antonarakis, Emmanuel S., Changxue Lu, Brandon Luber, et al.. (2016). AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.. Journal of Clinical Oncology. 34(15_suppl). 5012–5012. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact